FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $0.86, $0.21 better than the analyst estimate of $0.65. Revenue for the quarter came in at $41.2 million versus the consensus estimate of $45.41 million.
First Quarter 2021
Total revenue for Q1 2021 was $41.2 million, compared to $46.0 million in Q1 2020, primarily reflecting decreased product sales of RYANODEX® and royalty revenue of BENDEKA®.
Q1 2021 net loss was $0.4 million, or $0.03 per basic and... More
